Norfloxacin treatment on E. coli in the urinary tract of mice: Effect of probiotic Lactobacilli

Autores
Silva, Clara del Valle; Nader, Maria Elena Fatima
Año de publicación
2006
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
This study was perfomed to evaluate the effect of the treatment of norfloxacin, as an antimicrobial agent, on the uropathogenic Escherichia coli colonization in mice, complemented by Lactobacilli as probiotics. Norfloxacin (5.5 mg. Kg-1 dose) was administred orally before and after the challenge with E. coli. The animals were also inoculated intra-urethrally with agarose beads containing L. fermentum. The population of the microorganisms in the urogenital tract was measured various days throughout the study. Using either 1 or 3 doses of norfloxacion befor or after the animal had been challenged with E. coli bacteria, reduced the E. coli population the urinary tract. The Norfloxacin treatment after the animals were administered 1 or 3 doses of agarose beads of lactobacilli significantly affected the viability of the lactic acid bacteria in all of the urinary tract organs and the number of E. coly (regardless to when the antibiotic was inoculated) was lower in the mice treated with lactobacilli than in the non-lactobacilli treated mice. Eventhough the survival of the lactobacilli was highly affected by the norfloxacin treatment, the uropathogenic E. coli colonization always decreased more than the lactobacilli population did and often completely disappeared in those animals which were treated with both norfloxacin and probiotic lactobacilli. Through this experimental model one can conclude that lactobacilli increases the effectiveness of the norfloxacin medication in the prevention and treatment of UTI produced by E. coli. Further studies are being performed to determine the mechanisms involved in this probiotic effect.
Fil: Silva, Clara del Valle. Universidad Nacional de Tucumán. Facultad de Bioquímica, Química y Farmacia; Argentina
Fil: Nader, Maria Elena Fatima. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; Argentina
Materia
Probiotics
Norfloxacin
Urinary Tract Infections
Prevention
E. Coli
L. Fermentum
Recurrence
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/58961

id CONICETDig_7db276b0203fbc9c81ecb0e264e71170
oai_identifier_str oai:ri.conicet.gov.ar:11336/58961
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Norfloxacin treatment on E. coli in the urinary tract of mice: Effect of probiotic LactobacilliSilva, Clara del ValleNader, Maria Elena FatimaProbioticsNorfloxacinUrinary Tract InfectionsPreventionE. ColiL. FermentumRecurrencehttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1This study was perfomed to evaluate the effect of the treatment of norfloxacin, as an antimicrobial agent, on the uropathogenic Escherichia coli colonization in mice, complemented by Lactobacilli as probiotics. Norfloxacin (5.5 mg. Kg-1 dose) was administred orally before and after the challenge with E. coli. The animals were also inoculated intra-urethrally with agarose beads containing L. fermentum. The population of the microorganisms in the urogenital tract was measured various days throughout the study. Using either 1 or 3 doses of norfloxacion befor or after the animal had been challenged with E. coli bacteria, reduced the E. coli population the urinary tract. The Norfloxacin treatment after the animals were administered 1 or 3 doses of agarose beads of lactobacilli significantly affected the viability of the lactic acid bacteria in all of the urinary tract organs and the number of E. coly (regardless to when the antibiotic was inoculated) was lower in the mice treated with lactobacilli than in the non-lactobacilli treated mice. Eventhough the survival of the lactobacilli was highly affected by the norfloxacin treatment, the uropathogenic E. coli colonization always decreased more than the lactobacilli population did and often completely disappeared in those animals which were treated with both norfloxacin and probiotic lactobacilli. Through this experimental model one can conclude that lactobacilli increases the effectiveness of the norfloxacin medication in the prevention and treatment of UTI produced by E. coli. Further studies are being performed to determine the mechanisms involved in this probiotic effect.Fil: Silva, Clara del Valle. Universidad Nacional de Tucumán. Facultad de Bioquímica, Química y Farmacia; ArgentinaFil: Nader, Maria Elena Fatima. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; ArgentinaMedwell online2006-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/58961Silva, Clara del Valle; Nader, Maria Elena Fatima; Norfloxacin treatment on E. coli in the urinary tract of mice: Effect of probiotic Lactobacilli; Medwell online; International Journal of Molecular Medicine and Advances Sciences; 2; 4; 12-2006; 360-3651813-176x1994-4624CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.medwelljournals.com/archive.php?jid=1813-176xinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:45:13Zoai:ri.conicet.gov.ar:11336/58961instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:45:14.264CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Norfloxacin treatment on E. coli in the urinary tract of mice: Effect of probiotic Lactobacilli
title Norfloxacin treatment on E. coli in the urinary tract of mice: Effect of probiotic Lactobacilli
spellingShingle Norfloxacin treatment on E. coli in the urinary tract of mice: Effect of probiotic Lactobacilli
Silva, Clara del Valle
Probiotics
Norfloxacin
Urinary Tract Infections
Prevention
E. Coli
L. Fermentum
Recurrence
title_short Norfloxacin treatment on E. coli in the urinary tract of mice: Effect of probiotic Lactobacilli
title_full Norfloxacin treatment on E. coli in the urinary tract of mice: Effect of probiotic Lactobacilli
title_fullStr Norfloxacin treatment on E. coli in the urinary tract of mice: Effect of probiotic Lactobacilli
title_full_unstemmed Norfloxacin treatment on E. coli in the urinary tract of mice: Effect of probiotic Lactobacilli
title_sort Norfloxacin treatment on E. coli in the urinary tract of mice: Effect of probiotic Lactobacilli
dc.creator.none.fl_str_mv Silva, Clara del Valle
Nader, Maria Elena Fatima
author Silva, Clara del Valle
author_facet Silva, Clara del Valle
Nader, Maria Elena Fatima
author_role author
author2 Nader, Maria Elena Fatima
author2_role author
dc.subject.none.fl_str_mv Probiotics
Norfloxacin
Urinary Tract Infections
Prevention
E. Coli
L. Fermentum
Recurrence
topic Probiotics
Norfloxacin
Urinary Tract Infections
Prevention
E. Coli
L. Fermentum
Recurrence
purl_subject.fl_str_mv https://purl.org/becyt/ford/1.6
https://purl.org/becyt/ford/1
dc.description.none.fl_txt_mv This study was perfomed to evaluate the effect of the treatment of norfloxacin, as an antimicrobial agent, on the uropathogenic Escherichia coli colonization in mice, complemented by Lactobacilli as probiotics. Norfloxacin (5.5 mg. Kg-1 dose) was administred orally before and after the challenge with E. coli. The animals were also inoculated intra-urethrally with agarose beads containing L. fermentum. The population of the microorganisms in the urogenital tract was measured various days throughout the study. Using either 1 or 3 doses of norfloxacion befor or after the animal had been challenged with E. coli bacteria, reduced the E. coli population the urinary tract. The Norfloxacin treatment after the animals were administered 1 or 3 doses of agarose beads of lactobacilli significantly affected the viability of the lactic acid bacteria in all of the urinary tract organs and the number of E. coly (regardless to when the antibiotic was inoculated) was lower in the mice treated with lactobacilli than in the non-lactobacilli treated mice. Eventhough the survival of the lactobacilli was highly affected by the norfloxacin treatment, the uropathogenic E. coli colonization always decreased more than the lactobacilli population did and often completely disappeared in those animals which were treated with both norfloxacin and probiotic lactobacilli. Through this experimental model one can conclude that lactobacilli increases the effectiveness of the norfloxacin medication in the prevention and treatment of UTI produced by E. coli. Further studies are being performed to determine the mechanisms involved in this probiotic effect.
Fil: Silva, Clara del Valle. Universidad Nacional de Tucumán. Facultad de Bioquímica, Química y Farmacia; Argentina
Fil: Nader, Maria Elena Fatima. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; Argentina
description This study was perfomed to evaluate the effect of the treatment of norfloxacin, as an antimicrobial agent, on the uropathogenic Escherichia coli colonization in mice, complemented by Lactobacilli as probiotics. Norfloxacin (5.5 mg. Kg-1 dose) was administred orally before and after the challenge with E. coli. The animals were also inoculated intra-urethrally with agarose beads containing L. fermentum. The population of the microorganisms in the urogenital tract was measured various days throughout the study. Using either 1 or 3 doses of norfloxacion befor or after the animal had been challenged with E. coli bacteria, reduced the E. coli population the urinary tract. The Norfloxacin treatment after the animals were administered 1 or 3 doses of agarose beads of lactobacilli significantly affected the viability of the lactic acid bacteria in all of the urinary tract organs and the number of E. coly (regardless to when the antibiotic was inoculated) was lower in the mice treated with lactobacilli than in the non-lactobacilli treated mice. Eventhough the survival of the lactobacilli was highly affected by the norfloxacin treatment, the uropathogenic E. coli colonization always decreased more than the lactobacilli population did and often completely disappeared in those animals which were treated with both norfloxacin and probiotic lactobacilli. Through this experimental model one can conclude that lactobacilli increases the effectiveness of the norfloxacin medication in the prevention and treatment of UTI produced by E. coli. Further studies are being performed to determine the mechanisms involved in this probiotic effect.
publishDate 2006
dc.date.none.fl_str_mv 2006-12
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/58961
Silva, Clara del Valle; Nader, Maria Elena Fatima; Norfloxacin treatment on E. coli in the urinary tract of mice: Effect of probiotic Lactobacilli; Medwell online; International Journal of Molecular Medicine and Advances Sciences; 2; 4; 12-2006; 360-365
1813-176x
1994-4624
CONICET Digital
CONICET
url http://hdl.handle.net/11336/58961
identifier_str_mv Silva, Clara del Valle; Nader, Maria Elena Fatima; Norfloxacin treatment on E. coli in the urinary tract of mice: Effect of probiotic Lactobacilli; Medwell online; International Journal of Molecular Medicine and Advances Sciences; 2; 4; 12-2006; 360-365
1813-176x
1994-4624
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.medwelljournals.com/archive.php?jid=1813-176x
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Medwell online
publisher.none.fl_str_mv Medwell online
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613421270564864
score 13.070432